QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
QQQ   311.72 (+3.59%)
AAPL   150.82 (+3.71%)
MSFT   264.60 (+4.69%)
META   188.77 (+23.28%)
GOOGL   107.74 (+7.28%)
AMZN   112.91 (+7.38%)
TSLA   188.27 (+3.78%)
NVDA   217.09 (+3.66%)
NIO   11.96 (-1.16%)
BABA   109.74 (-2.73%)
AMD   88.31 (+4.34%)
T   20.28 (+0.50%)
MU   63.17 (+0.91%)
F   14.32 (+3.84%)
CGC   3.14 (+1.95%)
GE   83.94 (+1.97%)
DIS   113.21 (+3.49%)
AMC   6.08 (+6.48%)
PFE   44.34 (+0.84%)
PYPL   86.96 (+4.88%)
NFLX   366.89 (+1.35%)
NASDAQ:GHRS

GH Research - GHRS Stock Forecast, Price & News

$9.18
+0.09 (+0.99%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.80
$9.50
50-Day Range
$8.77
$12.30
52-Week Range
$8.46
$20.34
Volume
36,306 shs
Average Volume
80,655 shs
Market Capitalization
$463.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.25

GH Research MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
403.8% Upside
$46.25 Price Target
Short Interest
Bearish
8.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.44) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

810th out of 1,030 stocks

Pharmaceutical Preparations Industry

403rd out of 502 stocks


GHRS stock logo

About GH Research (NASDAQ:GHRS) Stock

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Stock News Headlines

Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Massachusetts General Hospital
GHRS.OQ - | Stock Price & Latest News | Reuters
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
New Psychedelics ETF Launches On NYSE Arca
GH Research Q2 2021 G&A Expenses $719K
GH Research Plc (GHRS)
See More Headlines
Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Company Calendar

Last Earnings
11/10/2022
Today
2/02/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GHRS
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.25
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+403.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-9,200,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.49 per share

Miscellaneous

Free Float
29,504,000
Market Cap
$463.78 million
Optionable
Not Optionable
Beta
0.85

Key Executives

  • Mr. Florian Schonharting M.Sc. (Econ) (Age 53)
    Co-Founder & Non-Exec. Chairman
  • Mr. Theis Terwey M.D. (Age 45)
    Co-Founder & CEO
  • Mr. Magnus Halle (Age 24)
    Co-Founder & MD of Ireland
  • Ms. Julie Ryan A.C.A. (Age 36)
    VP of Fin.













GHRS Stock - Frequently Asked Questions

Should I buy or sell GH Research stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings
or view top-rated stocks.

What is GH Research's stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month price targets for GH Research's shares. Their GHRS share price forecasts range from $33.00 to $66.00. On average, they expect the company's stock price to reach $46.25 in the next twelve months. This suggests a possible upside of 408.8% from the stock's current price.
View analysts price targets for GHRS
or view top-rated stocks among Wall Street analysts.

How have GHRS shares performed in 2023?

GH Research's stock was trading at $9.72 at the start of the year. Since then, GHRS shares have decreased by 6.5% and is now trading at $9.09.
View the best growth stocks for 2023 here
.

When is GH Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our GHRS earnings forecast
.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.16.

When did GH Research IPO?

(GHRS) raised $150 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is GH Research's stock symbol?

GH Research trades on the NASDAQ under the ticker symbol "GHRS."

Who are GH Research's major shareholders?

GH Research's stock is owned by many different retail and institutional investors. Top institutional investors include Cornerstone Investment Partners LLC (0.03%), Exchange Traded Concepts LLC (0.02%) and Exchange Traded Concepts LLC (0.02%).

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GH Research's stock price today?

One share of GHRS stock can currently be purchased for approximately $9.09.

How much money does GH Research make?

GH Research (NASDAQ:GHRS) has a market capitalization of $459.23 million. The company earns $-9,200,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How can I contact GH Research?

The official website for the company is www.ghres.com. The company can be reached via phone at 353-1437-8443 or via email at investors@ghres.com.

This page (NASDAQ:GHRS) was last updated on 2/2/2023 by MarketBeat.com Staff